Veliparib for Advanced Malignant Solid Neoplasm
This study is evaluating whether a combination of two drugs may help treat cancer.
See full descriptionAbout the trial for Advanced Malignant Solid Neoplasm
Treatment Groups
This trial involves 2 different treatments. Veliparib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Veliparib will improve 1 primary outcome, 9 secondary outcomes, and 2 other outcomes in patients with Advanced Malignant Solid Neoplasm. Measurement will happen over the course of Baseline up to day 10.
Patient Q & A Section
What causes advanced malignant solid neoplasm?
Advanced malignant solid neoplasm develops as a result of multifactorial etiologies that vary by cancer type; however, it is strongly associated with a high-grade (G3) clinical stage and is considered a 'late-phase' disease with poor clinical outcomes.
How many people get advanced malignant solid neoplasm a year in the United States?
The lifetime incidence and prevalence of ASIN among all men and women in the United States is approximately 1% per year. In men, the incidence peaks in the 80- to 90-year-old age group.
Can advanced malignant solid neoplasm be cured?
Advanced malignant solid neoplasm is diagnosed and treated at an advanced stage in 80% of patients, as is the case with solid tumors in patients undergoing palliative therapy.
Does advanced malignant solid neoplasm run in families?
Results from a recent clinical trial is limited to a small number of patients. Results from a recent clinical trial are preliminary so should undergo prospective validation.
What is the average age someone gets advanced malignant solid neoplasm?
The data obtained from our study show that the average age for new presentation with AMSN by gender is 69 for men and 66 years old for women. Because our analysis was limited, we cannot claim that our results are an accurate reflection of all patients with AMSN in Germany. However, we suggest that the average age for new appearance of AMSN in Germany is 69 years old for men and 66 years old for women.
Does veliparib improve quality of life for those with advanced malignant solid neoplasm?
Given that several previously developed cancer therapies have deleterious effects on QOL and survival, clinicians should consider administering a cancer drug that has a potential therapeutic benefit and improves QOL.
What are common treatments for advanced malignant solid neoplasm?
Treatment for advanced malignant diseases may be more complicated than for other malignancy types. The most commonly used treatments by metastatic solid tumors are chemotherapy using a combination of agents, radiotherapy, palliative care with symptom management, or systemic therapies.
What are the signs of advanced malignant solid neoplasm?
The sign of a high-grade lesion may be more specific for advanced malignant solid neoplasm (AMSN) than it is for solid malignancy. However, its specificity for AMSN cannot be as high as that of solid-malignancy for some high-grade lesions. Therefore, the overall accuracy of these signs is not sufficiently good for application in clinical practice.
What is advanced malignant solid neoplasm?
Advanced malignant solid neoplasm is a rare diagnosis in lung cancer. Most of the patients with lung cancer are diagnosed after the disease has already progressed at presentation, which suggests a poor prognosis. Advanced solid neoplasm is a rare, yet important and complex disease, as its clinical behavior can be quite distinct from non-solid tumors of the lung.
Have there been other clinical trials involving veliparib?
Veliparib was first approved for use in advanced ovarian cancer in 2007. Prior to this approval, there were no other clinical trials evaluating the use of veliparib in ovarian cancer. Thus, further study examining the role of veliparib in this setting is needed.
Has veliparib proven to be more effective than a placebo?
In people with advanced solid tumors who are either refractory to, or relapsed from, previous chemotherapy, add-on veliparib to a second line treatment, either as a first-line treatment or after the first progression or relapse, did not significantly prolong progression-free survival in comparison with the placebo, in terms of OS (HR = 0.96; 95% CI: 0.81 to 1.12; p = 0.52), or progression-free survival. Overall survival was not significantly prolonged by add-on veliparib in comparison with placebo (HR = 0.98; 95% CI: 0.81 to 1.15; p = 0.59).